Stock Watch: Brace For European Biotech Departures From NASDAQ
Waning Investor Appetite And Cost Cutting May Drive Biotechs Home
A NASDAQ listing has been the pinnacle for non-US biotech companies because it brings access to more specialist investors and a larger capital base. But the appetite for – and aftermarket performance of – this biotech tourism is cycle-dependent.
